369 related articles for article (PubMed ID: 25349154)
21. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
22. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
23. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
25. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
[TBL] [Abstract][Full Text] [Related]
26. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
[TBL] [Abstract][Full Text] [Related]
27. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
Mian YA; Zeleznik-Le NJ
Leuk Res; 2016 Jul; 46():51-60. PubMed ID: 27123834
[TBL] [Abstract][Full Text] [Related]
28. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
[TBL] [Abstract][Full Text] [Related]
29. Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia.
Zhao L; Zhang P; Galbo PM; Zhou X; Aryal S; Qiu S; Zhang H; Zhou Y; Li C; Zheng D; Bhatia R; Lu R
Blood Adv; 2021 Nov; 5(22):4727-4740. PubMed ID: 34597364
[TBL] [Abstract][Full Text] [Related]
30. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
[TBL] [Abstract][Full Text] [Related]
31. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
32. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
33. Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
Liu J; Qin YZ; Yang S; Wang Y; Chang YJ; Zhao T; Jiang Q; Huang XJ
Ann Hematol; 2017 Apr; 96(4):567-574. PubMed ID: 28054140
[TBL] [Abstract][Full Text] [Related]
34. Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway.
Wang F; Wu P; Gong S; Chen Y; Gao J; Wang S; Shen Q; Tao H; Hua F; Zhou Z; Zou Z; Ma T; Jia Y
Cell Signal; 2020 Aug; 72():109643. PubMed ID: 32320859
[TBL] [Abstract][Full Text] [Related]
35. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
37. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
[TBL] [Abstract][Full Text] [Related]
38. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
[TBL] [Abstract][Full Text] [Related]
39. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
